Cargando…

Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV

Hot-melt granulation is a technique used to obtain granules by dispersing a drug in polymers at a high temperature. Tenofovir, an antiretroviral drug with proven activity as a vaginal microbicide, was dispersed in melted Gelucire(®) (or a mixture of different Gelucire(®)) to obtain drug-loaded granu...

Descripción completa

Detalles Bibliográficos
Autores principales: Notario-Pérez, Fernando, Cazorla-Luna, Raúl, Martín-Illana, Araceli, Ruiz-Caro, Roberto, Peña, Juan, Veiga, María-Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470605/
https://www.ncbi.nlm.nih.gov/pubmed/30897790
http://dx.doi.org/10.3390/pharmaceutics11030137
_version_ 1783411835887681536
author Notario-Pérez, Fernando
Cazorla-Luna, Raúl
Martín-Illana, Araceli
Ruiz-Caro, Roberto
Peña, Juan
Veiga, María-Dolores
author_facet Notario-Pérez, Fernando
Cazorla-Luna, Raúl
Martín-Illana, Araceli
Ruiz-Caro, Roberto
Peña, Juan
Veiga, María-Dolores
author_sort Notario-Pérez, Fernando
collection PubMed
description Hot-melt granulation is a technique used to obtain granules by dispersing a drug in polymers at a high temperature. Tenofovir, an antiretroviral drug with proven activity as a vaginal microbicide, was dispersed in melted Gelucire(®) (or a mixture of different Gelucire(®)) to obtain drug-loaded granules. Studies performed on the granules proved that the drug is not altered in the hot-melt granulation process. The granules obtained were included in a matrix formed by the hydrophilic polymers hydroxypropylmethylcellulose and chitosan to obtain vaginal tablets that combine different mechanisms of controlled release: The Gelucire(®) needs to soften to allow the release of the Tenofovir, and the hydrophilic polymers must form a gel so the drug can diffuse through it. The studies performed with the tablets were swelling behavior, Tenofovir release, and ex vivo mucoadhesion. The tablets containing granules obtained with Tenofovir and Gelucire(®) 43/01 in a ratio of 1:2 in a matrix formed by hydroxypropylmethylcellulose and chitosan in a ratio of 1.9:1 were selected as the optimal formulation, since they release Tenofovir in a sustained manner over 216h and remain attached to the vaginal mucosa throughout. A weekly administration of these tablets would therefore offer women protection against the sexual transmission of HIV.
format Online
Article
Text
id pubmed-6470605
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64706052019-04-27 Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV Notario-Pérez, Fernando Cazorla-Luna, Raúl Martín-Illana, Araceli Ruiz-Caro, Roberto Peña, Juan Veiga, María-Dolores Pharmaceutics Article Hot-melt granulation is a technique used to obtain granules by dispersing a drug in polymers at a high temperature. Tenofovir, an antiretroviral drug with proven activity as a vaginal microbicide, was dispersed in melted Gelucire(®) (or a mixture of different Gelucire(®)) to obtain drug-loaded granules. Studies performed on the granules proved that the drug is not altered in the hot-melt granulation process. The granules obtained were included in a matrix formed by the hydrophilic polymers hydroxypropylmethylcellulose and chitosan to obtain vaginal tablets that combine different mechanisms of controlled release: The Gelucire(®) needs to soften to allow the release of the Tenofovir, and the hydrophilic polymers must form a gel so the drug can diffuse through it. The studies performed with the tablets were swelling behavior, Tenofovir release, and ex vivo mucoadhesion. The tablets containing granules obtained with Tenofovir and Gelucire(®) 43/01 in a ratio of 1:2 in a matrix formed by hydroxypropylmethylcellulose and chitosan in a ratio of 1.9:1 were selected as the optimal formulation, since they release Tenofovir in a sustained manner over 216h and remain attached to the vaginal mucosa throughout. A weekly administration of these tablets would therefore offer women protection against the sexual transmission of HIV. MDPI 2019-03-20 /pmc/articles/PMC6470605/ /pubmed/30897790 http://dx.doi.org/10.3390/pharmaceutics11030137 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Notario-Pérez, Fernando
Cazorla-Luna, Raúl
Martín-Illana, Araceli
Ruiz-Caro, Roberto
Peña, Juan
Veiga, María-Dolores
Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV
title Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV
title_full Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV
title_fullStr Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV
title_full_unstemmed Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV
title_short Tenofovir Hot-Melt Granulation using Gelucire(®) to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV
title_sort tenofovir hot-melt granulation using gelucire(®) to develop sustained-release vaginal systems for weekly protection against sexual transmission of hiv
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470605/
https://www.ncbi.nlm.nih.gov/pubmed/30897790
http://dx.doi.org/10.3390/pharmaceutics11030137
work_keys_str_mv AT notarioperezfernando tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv
AT cazorlalunaraul tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv
AT martinillanaaraceli tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv
AT ruizcaroroberto tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv
AT penajuan tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv
AT veigamariadolores tenofovirhotmeltgranulationusinggeluciretodevelopsustainedreleasevaginalsystemsforweeklyprotectionagainstsexualtransmissionofhiv